ReviewCanadian family physician Medecin de famille canadien2026
Approach to osteoporosis diagnosis and fracture risk management in primary care.
Review in Canadian family physician Medecin de famille canadien, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo outline strategies to reduce osteoporosis-related fracture risk through pharmacologic and nonpharmacologic interventions; to examine the role of the Fracture Risk Assessment Tool (FRAX) and bone mineral density (BMD) testing in fracture risk evaluation and periodic monitoring; and to outline evidence-informed interventions for optimizing nutrition, exercise, and pharmacotherapy. SOURCES OF INFORMATION: Recent Canadian guidelines from Osteoporosis Canada, the Canadian Task Force on Preventive Health Care, and the Society of Obstetricians and Gynaecologists of Canada. MAIN MESSAGE: Both BMD testing and FRAX are endorsed by Canadian guidelines for fracture risk assessment. Guidelines support clinical evaluation of fracture risk, particularly in females 65 years or older, with variations in age- and sex-specific screening recommendations between 50 and 64 years. Effective bone health management integrates pharmacologic and nonpharmacologic strategies to prevent falls and fractures.
conclusionGuidelines recommend prioritizing fracture risk screening in females 65 years or older with risk factor assessment and FRAX application. Evaluation should include assessment of fall risk and signs of undiagnosed vertebral fractures. Risk assessment and shared decision making should guide further evaluation with BMD testing. Osteoporosis Canada suggests targeting screening as per fracture risk in postmenopausal females 65 years or younger and males 50 years or older, noting limited supporting evidence. Adults 50 years or older should engage in balance, functional, and resistance training twice weekly, and follow Health Canada's recommendations for calcium and vitamin D intake, including a vitamin D supplement of 400 IU daily. Pharmacologic therapy is recommended for those with prior hip or vertebral fracture, 2 or more osteoporotic fractures, a 10-year fracture risk 20% or higher, or a T-score -2.5 or less and age 70 years or older, guided by patient values and preference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.